Neutrophil Function, Oxidative Burst
Use
This test, also known as the classic dihydrorhodamine (DHR) 123 assay, assesses neutrophil oxidative burst capability via flow cytometry and is used to aid in the diagnosis of chronic granulomatous disease (CGD) by evaluating the functional integrity of neutrophils' reactive oxygen species generation. It can help distinguish CGD and related conditions by measuring neutrophil responses before and after stimulation.
Special Instructions
Also referred to as the DHR assay or Rhodamine assay. Available at Quest Diagnostics Nichols Institute. The performing lab identifies it under the category of cellular immunology (leukocyte function). The test is not available for New York patient testing per a policy update effective April 3, 2023.
Limitations
Not provided.
Methodology
Cell-based / Cytometry (Flow Cytometry)
Biomarkers
Result Turnaround Time
Not provided.
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
Not provided
Minimum Volume
Not provided
Container
heparinized whole blood